Actively Recruiting
A Retrospective Analysis of Outcomes in Patients With Hepatorenal Syndrome at Methodist Dallas Medical Center
Led by Methodist Health System · Updated on 2026-05-01
500
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Hepatorenal syndrome (HRS) is a condition causing acute kidney injury in patients with liver disease, often due to circulatory changes from vasodilators like nitric oxide. It presents with elevated serum creatinine, benign urine sediment, and low urine sodium. The study evaluates outcomes in patients with HRS by comparing various treatment methods to better understand their effects and support treatment decisions. The research is a retrospective analysis of patients with HRS, focusing on treatments including vasoconstrictors, albumin, continuous renal replacement therapy (CRRT), Molecular Adsorbent Recirculating System (MARS), and transjugular intrahepatic portosystemic shunts (TIPS). CRRT is considered especially for patients with severe electrolyte imbalances and can serve as a bridge to liver transplantation, although it carries risks such as low blood pressure and cardiac events. TIPS may improve kidney function by reducing portal pressure. Participants are patients over 18 hospitalized between April 2019 and April 2023 diagnosed with HRS. Researchers will review medical records to assess treatment outcomes, focusing on primary outcomes for HRS-AKI patients over four years and post-transplant mortality rates. The study involves no interventions or additional procedures beyond data analysis. The total participation involves reviewing historical data, with no direct patient involvement or follow-up.
CONDITIONS
Brief Title
A Retrospective Analysis of Outcomes in Patients With Hepatorenal Syndrome at Methodist Dallas Medical Center
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients older than 18 years hospitalized between April 1, 2019, and April 1, 2023
- Diagnosed with HRS-AKI or developed HRS during hospital stay
- Presence of cirrhosis, acute liver failure, or acute-on-chronic liver failure
- Increase in serum creatinine of 0.3 mg/dL within 48 hours or 50% from baseline, or low urine output for at least 6 hours
- No response after at least 2 days of diuretic withdrawal and albumin treatment
- Absence of shock
- No current or recent use of nephrotoxic drugs
- No parenchymal kidney disease
- Suggestion of renal vasoconstriction with fractional excretion of sodium less than 0.2%
You will not qualify if you...
- Patients younger than 18 years
- Hospitalized patients between April 1, 2019, and April 1, 2023 without a diagnosis of HRS-AKI
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 4 years
Participants who undergo routine care for Hepatorenal Syndrome are observed to analyze outcomes based on various treatment modalities such as vasoconstrictors, albumin, CRRT, MARS, and TIPS.
Visits as part of routine clinical care
Trial Site Locations
Total: 1 location
1
Liver Institute of Methodist Dallas Medical Center
Dallas, Texas, United States, 75203
Actively Recruiting
Research Team
C
Colette Ngo Ndjom, MS
L
Loretta W Bedell, MPH
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here